自噬抑制剂在结直肠癌治疗中的应用综述

Q4 Medicine

Italian journal of anatomy and embryology Pub Date : 2022-12-27 DOI:10.36253/ijae-13788

M. Ceci, M. Iezzi, M. Trerotola

{"title":"自噬抑制剂在结直肠癌治疗中的应用综述","authors":"M. Ceci, M. Iezzi, M. Trerotola","doi":"10.36253/ijae-13788","DOIUrl":null,"url":null,"abstract":"Colorectal cancer (CRC) is the third most frequent cancer. The first-line adjuvant or neoadjuvant chemotherapy is represented by 5-fluorouracil (5-FU) but its application is limited due to induction of chemoresistance. Recent studies showed that the 5-FU resistance in CRC is closely related to the activation of autophagy. During human carcinogenesis, autophagy has been demonstrated to play opposite roles of inhibitor or promoter of malignant progression depending on initial or advanced stages of growth. Currently, the autophagy inhibitor chloroquine (CQ) and its derivate, hydroxychloroquine (HCQ), are the only Food and Drug Administration (FDA)-approved drugs for clinical use. This review summarizes recent findings on the possible employment of autophagy inhibitors to overcome chemoresistance engaged in the CRC.","PeriodicalId":14636,"journal":{"name":"Italian journal of anatomy and embryology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Autophagy inhibitors in the treatment of colorectal cancer: a brief review\",\"authors\":\"M. Ceci, M. Iezzi, M. Trerotola\",\"doi\":\"10.36253/ijae-13788\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Colorectal cancer (CRC) is the third most frequent cancer. The first-line adjuvant or neoadjuvant chemotherapy is represented by 5-fluorouracil (5-FU) but its application is limited due to induction of chemoresistance. Recent studies showed that the 5-FU resistance in CRC is closely related to the activation of autophagy. During human carcinogenesis, autophagy has been demonstrated to play opposite roles of inhibitor or promoter of malignant progression depending on initial or advanced stages of growth. Currently, the autophagy inhibitor chloroquine (CQ) and its derivate, hydroxychloroquine (HCQ), are the only Food and Drug Administration (FDA)-approved drugs for clinical use. This review summarizes recent findings on the possible employment of autophagy inhibitors to overcome chemoresistance engaged in the CRC.\",\"PeriodicalId\":14636,\"journal\":{\"name\":\"Italian journal of anatomy and embryology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Italian journal of anatomy and embryology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36253/ijae-13788\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian journal of anatomy and embryology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36253/ijae-13788","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

癌症（CRC）是癌症发病率第三高的肿瘤。一线辅助或新辅助化疗以5-氟尿嘧啶（5-FU）为代表，但由于化疗耐药性的诱导，其应用受到限制。最近的研究表明，CRC的5-FU耐药性与自噬的激活密切相关。在人类致癌过程中，根据生长的初始或晚期，自噬已被证明在恶性进展的抑制剂或启动子中发挥相反的作用。目前，自噬抑制剂氯喹（CQ）及其衍生物羟氯喹（HCQ）是美国食品药品监督管理局（FDA）批准的唯一临床使用药物。这篇综述总结了最近关于可能使用自噬抑制剂来克服CRC中的化学耐药性的研究结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Autophagy inhibitors in the treatment of colorectal cancer: a brief review

Colorectal cancer (CRC) is the third most frequent cancer. The first-line adjuvant or neoadjuvant chemotherapy is represented by 5-fluorouracil (5-FU) but its application is limited due to induction of chemoresistance. Recent studies showed that the 5-FU resistance in CRC is closely related to the activation of autophagy. During human carcinogenesis, autophagy has been demonstrated to play opposite roles of inhibitor or promoter of malignant progression depending on initial or advanced stages of growth. Currently, the autophagy inhibitor chloroquine (CQ) and its derivate, hydroxychloroquine (HCQ), are the only Food and Drug Administration (FDA)-approved drugs for clinical use. This review summarizes recent findings on the possible employment of autophagy inhibitors to overcome chemoresistance engaged in the CRC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Italian journal of anatomy and embryology Medicine-Embryology

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： The Italian Journal of Anatomy and Embryology, founded in 1901 by Giulio Chiarugi, Anatomist at Florence University, is a peer-reviewed journal sponsored by the Italian Society of Anatomy and Embryology. The journal publishes original papers, invited review articles, historical article, commentaries, obituitary, and book reviews. Its main focus is to understand anatomy through an analysis of structure, function, development and evolution. Priority will be given to studies of that clearly articulate their relevance to the anatomical community. Focal areas include: experimental studies, contributions based on molecular and cell biology and on the application of modern imaging techniques; comparative functional morphology; developmental biology; functional human anatomy; methodological innovations in anatomical research; significant advances in anatomical education. Studies that are essentially descriptive anatomy are appropriate only if they communicate clearly a broader functional or evolutionary significance. All papers should be submitted in English and must be original works that are unpublished and not under consideration by another journal. An international Editorial Board and reviewers from the anatomical disciplines guarantee a rapid review of your paper within two to three weeks after submission.